•
Sep 30, 2022
Nektar Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
Nektar Therapeutics reported a revenue of $23.6 million and a net loss of $59.0 million for the third quarter of 2022. The company's cash and investments in marketable securities were approximately $546.4 million as of September 30, 2022, expected to support strategic development activities and operations through the middle of 2025.
Advanced biologics pipeline in oncology and immunology.
Presented positive proof-of-concept data for NKTR-358 in atopic dermatitis with partner Eli Lilly.
Plan to launch a comparative study of NKTR-255 in large B-cell lymphoma.
Planning presentations at SITC and ASH for preclinical and clinical programs.